Thalassaemia is a genetic blood disorder where the body makes an abnormal form of hemoglobin – the protein in red blood cells that carries oxygen throughout the body.
Patients diagnosed with Thalassaemia may require regular blood transfusions to raise their hemoglobin blood levels. This can lead to iron build-up in the body’s tissue and organs – also referred to as iron overload. As iron can be toxic, too much of it can damage tissue. Excessive iron accumulates in the heart, liver, lungs, brain, and other organs, which highly increases the risk of other diseases and even life-threatening conditions.
If a patient with Thalassemia is experiencing iron overload from frequent blood transfusions, they may require an iron removal or chelation therapy. One medication approved for this is Desferal™, which is infused subcutaneously using an infusion pump and infusion set. Desferal™ is given over a 8-12 hour period, often overnight. The treatment can be performed daily, or 5-7 times a week.*
* According to Desferal™ Summary of Product Characteristics (SPC) by Novartis Pharmaceuticals UK Ltd.
neria™ infusion sets are tested (in vitro) for use with Desferal™.1
|Insertion angle||90 degrees|
|Needle / Introducer needle guage||G27 or G29|
|Needle lengths||6, 8, 10 or 12 mm|
|Tubing lengths||60, 80, 110 cm|
|Priming volumes||60 cm @ 0.10 ml
80 cm @ 0.12 ml
110 cm @ 0.15 ml
1. Statement - Overview of Drug/Device Compatibility Test for the neria™ Range. 24. February 2020. AP-020446-MM. Data on file. Unomedical A/S.
Find relevant clinical literature about thalassaemia and continuous subcutaneous infusion management. below:
G C F Chan, D M W Ng, D Y T Fong, S Y Ha, Y L Lau
Am J Hematol. 2004 Aug;76(4):398-404
Rosario Di Maggio, Aurelio Maggio
Br J Haematol 2017 Sep;178(5):676-688
Kanjaksha Ghosh, Kinjalka Ghosh
Indian J Med Res. 2018 Oct;148(4):369-372
Beate Bittner, Wolfgang Richter, Johannes Schmidt
BioDrugs 2018 Oct;32(5):425-440
Jennifer McLenon, Mary A M Rogers
J Adv Nurs. 2019 Jan;75(1):30-42